GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cortigent Inc.
Cortigent is a biotech company developing therapies to restore function after nervous system injury. Its stock price represents a venture capital bet on the success of its technology. The chart reflects the high volatility associated with news about clinical trials of its candidates.
Share prices of companies in the market segment - Neuro
Cortigent, Inc. is a bioelectronic medical company developing technologies to restore function lost due to nervous system injuries. We've categorized it under the "Neurology" category, and the chart below shows how the market values companies operating at the intersection of medicine and high technology.
Broad Market Index - GURU.Markets
Cortigent is a bioelectronic medical company developing technologies to restore lost function in patients with neurological diseases. As a component of the GURU.Markets index, it is at the forefront of scientific advances. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CRGT - Daily change in the company's share price Cortigent Inc.
Cortigent, Inc.'s daily price change reflects the high volatility inherent in biotech companies. This metric measures its sensitivity to news about the development of its neurostimulation devices, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Neuro
Cortigent develops neuromodulation technologies for restoring function after stroke and other neurological injuries. This is a cutting-edge and risky area of medical technology. The chart below shows the volatility in this sector, reflecting the high potential and risks associated with CRGT's developments.
Daily change in the price of a broad market stock, index - GURU.Markets
Cortigent is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cortigent Inc.
Cortigent, Inc.'s year-over-year performance is a story about the development of its neurostimulation technologies. Its market capitalization over the next 12 months depends entirely on progress in clinical trials of its devices for rehabilitation after stroke and other injuries. Success could offer new hope for millions of patients and be a breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Neuro
Cortigent, Inc. is a bioelectronics company developing technologies to restore function after neurological injuries. Its stock price is extremely volatile, reflecting investor confidence in its breakthrough scientific potential rather than its current financial performance, which is typical for this speculative sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cortigent, with its neurostimulation technologies, is a bet on the future of medicine. Its performance, compared to the market, is completely unrelated to economics. It's a long-term bet that its technology will help patients with nervous system damage, which, if successful, will lead to explosive growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cortigent Inc.
Cortigent is a bioelectronics company developing therapies for injury rehabilitation. Its monthly growth is entirely dependent on progress in its clinical programs. News of the trial results for its neurostimulation platform is a key driver.
Monthly dynamics of market capitalization of the market segment - Neuro
Cortigent develops neurotechnologies aimed at restoring functions lost due to injury or disease, such as spinal implants to restore movement. The chart below reflects the mood in the neuroscience sector, where such technologies offer great promise.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cortigent, Inc. is a biotech company developing treatments for neurological disorders. Its stock is a bet on the success of its scientific research. Its performance is entirely dependent on the results of clinical trials and partnerships and has no correlation to the market, making it a high-risk investment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cortigent Inc.
Shares of Cortigent, a biomedical company developing neurostimulation technologies, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials and the path to commercialization of their devices. The chart below shows how short-term scientific developments and investor expectations influence the stock's price.
Weekly dynamics of market capitalization of the market segment - Neuro
Cortigent develops technologies for restoring neurological function. This is a cutting-edge field of medicine, and the company's shares are driven by expectations of a technological breakthrough. The chart will show how much its performance is detached from the market and entirely dependent on news about clinical trials and developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cortigent is a neurotechnology company. This chart compares its weekly volatility to the market. It shows how its stock, like other early-stage companies, is driven by news about regulatory approvals and research progress, rather than by overall market trends.
Market capitalization of the company, segment and market as a whole
CRGT - Market capitalization of the company Cortigent Inc.
The valuation of Cortigent, Inc., a spinoff from Vivianco, is a bet on its neurostimulation technologies for stroke rehabilitation. The company's valuation depends on the success of its clinical trials and the commercialization of this cutting-edge medical technology. The chart shows the promise and risks associated with neuromodulation.
CRGT - Share of the company's market capitalization Cortigent Inc. within the market segment - Neuro
Cortigent's market share in the neuroscience sector reflects its focus on developing technologies to restore function lost due to injury or disease. Its market share is driven by its innovative neurostimulation devices, which can help patients after stroke or spinal cord injury.
Market capitalization of the market segment - Neuro
The chart below is a barometer of the neurotechnology and rehabilitation medicine market. Cortigent, Inc. is one of the innovators in this field. The dynamics on the chart reflect investor hopes for technologies that can help restore function after strokes and injuries.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market value of the hope of stroke recovery. Cortigent's market cap is the valuation of its neurostimulation technology for patient rehabilitation. The line shows how this medical innovation, aimed at improving quality of life, is competing for its share of the global economy.
Book value capitalization of the company, segment and market as a whole
CRGT - Book value capitalization of the company Cortigent Inc.
Cortigent, Inc.'s book value represents its scientific capital. The chart below reflects the valuation of its pipeline of developments in neuromodulation for stroke and trauma recovery. Growth in the pipeline reflects progress in clinical trials, which are the biotech company's primary asset.
CRGT - Share of the company's book capitalization Cortigent Inc. within the market segment - Neuro
Cortigent's core assets are its R&D centers and laboratories, where neuromodulation technologies are developed to restore functions lost due to injury or disease. The chart shows its share of this cutting-edge scientific infrastructure, which forms the physical foundation for its innovations.
Market segment balance sheet capitalization - Neuro
Against the backdrop of the capital-intensive pharmaceutical industry, Cortigent has chosen to create medical devices. Its business requires certified manufacturing facilities to produce its neurostimulators, making its model moderately capital-intensive.
Book value of all companies included in the broad market index - GURU.Markets
Cortigent develops neurostimulation technologies to restore functions lost due to injury or disease. The company's assets are not hospitals, but unique implantable devices and scientific developments. The chart below shows the financial weight behind this attempt to "repair" the nervous system.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cortigent Inc.
Cortigent develops technologies to restore function lost due to neurological diseases. Its market value is the valuation of its innovative platform. Investors are betting on its potential to help paralyzed people.
Market to book capitalization ratio in a market segment - Neuro
Cortigent, Inc. is a company developing neurotechnology to restore function lost due to injury or disease. Its value is based on the potential of its revolutionary technologies. This chart shows how its market valuation, reflecting hopes for medical breakthroughs, is many times greater than its current assets.
Market to book capitalization ratio for the market as a whole
Cortigent develops neurotechnologies to restore functions lost due to injury or disease. The company's market valuation, shown in this chart, is based on the potential of its innovative developments and patents. Investors evaluate the likelihood of a breakthrough in neuromodulation and the commercialization of these technologies.
Debts of the company, segment and market as a whole
CRGT - Company debts Cortigent Inc.
Cortigent, a neurotechnology company, uses raised capital to fund its high-tech and long-term research. This chart shows how the company spends funds on R&D and clinical trials of its devices aimed at restoring nervous system function, a capital-intensive process.
Market segment debts - Neuro
Cortigent (formerly Wicab) develops neurotechnological devices to assist people with vision or balance impairments. This is a cutting-edge but capital-intensive field. This chart shows how the company's debt policy reflects its need to fund lengthy and expensive research, clinical trials, and regulatory approval for its innovative products.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cortigent Inc.
FBS Global Limited is a construction company. Construction is a project-based business, requiring significant working capital to finance materials and labor until payment is received from the client. This chart shows the company's use of debt to support its operations.
Market segment debt to market segment book capitalization - Neuro
Cortigent develops neurotechnologies aimed at restoring functions lost due to nervous system injuries. This chart compares the company's debt load to the overall market capitalization of the entire sector. It shows how a company at the forefront of science funds its cutting-edge, yet long-term and risky, research.
Debt to book value of all companies in the market
Cortigent, Inc. develops neurotechnologies aimed at restoring function after nervous system injury. This is at the cutting edge of medicine, requiring massive, long-term investments in R&D. This graph of total market debt shows the company's risk appetite, which is critical to the company's ability to fund its breakthrough, yet highly risky, research.
P/E of the company, segment and market as a whole
P/E - Cortigent Inc.
For Cortigent, a neurotechnology company, the P/E ratio is irrelevant. The company has no stable profitability. Its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments to restore nervous system function and investors' belief in its success.
P/E of the market segment - Neuro
Cortigent, formerly known as a pioneer of human-computer interfaces, develops neuromodulation technologies to restore function in patients with neurological disorders such as paralysis. This chart shows the average valuation for the neuroscience sector, reflecting investor expectations for breakthrough technologies that could change lives.
P/E of the market as a whole
Cortigent (formerly Intelligent Bio Solutions) develops biosensor technologies for non-invasive testing, as well as neurostimulation devices for injury rehabilitation. This risk appetite chart helps understand how investors value companies working at the intersection of diagnostics and therapeutic devices.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cortigent Inc.
Cortigent (formerly Wicab) develops neuromodulation technologies, including the BrainPort device, which helps blind people "see" using language. This graph reflects future revenue expectations, which depend on the commercialization of this unique technology and its implementation in medical practice.
%20P%2FE%20Cortigent%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cortigent-Inc.&v=1772657812068 "Chart of the company's future (projected) P/E Cortigent Inc.")
Future (projected) P/E of the market segment - Neuro
Cortigent develops neurotechnologies aimed at restoring function after spinal cord injury and stroke. This chart reflects both the enormous promise and the risks. It shows how the market views its breakthrough scientific potential compared to other companies in the neurotech sector, where success could change lives, but the road ahead is long.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772657812094 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Cortigent develops neurotechnologies aimed at restoring function after nervous system injuries, such as stroke or spinal cord injury. The company's future depends on breakthrough research and investment. This chart, demonstrating market optimism, reflects investors' willingness to invest in long-term, capital-intensive projects in high-tech medical technology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772657812167 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cortigent Inc.
Cortigent develops neurotechnologies aimed at restoring function lost due to neurological diseases or injuries. While in the research phase, the company incurs significant R&D expenditures. This chart illustrates the financial trajectory of this pioneer in the field of neuromodulation, where investment in science is key to creating future value.
Profit of companies in the market segment - Neuro
Cortigent develops neuromodulation technologies to restore function in patients with nervous system injuries, such as strokes and spinal cord injuries. This graph, showing overall profitability in the sector, reflects the potential of breakthrough medical technologies. Cortigent's success could revolutionize rehabilitation and create a new market.
Overall market profit
Cortigent develops technologies to restore function lost due to neurological diseases, such as paralysis. This is at the forefront of neurotechnology. The company's value is determined by its scientific potential and ability to help patients, making it unaffected by short-term economic cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cortigent Inc.
Cortigent (formerly Wicab) develops neurotechnologies that help restore function lost due to injury or disease. Future revenue projections presented here are speculative and depend on the success of clinical trials and the commercialization of its innovative medical devices.
%20profit%20of%20the%20company%20Cortigent%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cortigent-Inc.&v=1772657812564 "Graph of future (projected) profit of the company Cortigent Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Cortigent develops neurotechnology platforms aimed at restoring function lost due to neurological diseases or injuries. This chart shows overall revenue forecasts for the neuroscience segment. It reflects analysts' expectations for breakthroughs in the treatment of brain and central nervous system diseases and the potential role of the company's technologies in these breakthroughs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772657812612 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Cortigent develops technologies to restore nervous system function. This is a cutting-edge field of medicine that requires extensive research and investment. This chart, reflecting investors' risk appetite, is critical for Cortigent. During periods of economic optimism, investors are more inclined to fund breakthrough but high-risk medical projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772657812697 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cortigent Inc.
Cortigent develops neurotechnologies aimed at restoring function lost due to injury or neurological disease. For a company with breakthrough technology still in development, this chart reflects hope. It shows a valuation based on investors' faith in its science, not current sales.
P/S market segment - Neuro
Cortigent, Inc. (formerly Tinnitus) develops neuromodulation technologies for the treatment of chronic tinnitus and other neurological conditions. The company's value is based on the potential of its medical devices. This chart reflects the premium the market is willing to pay for revenue in the neurotechnology sector, demonstrating investor confidence in the breakthrough potential of Cortigent's developments.
P/S of the market as a whole
Cortigent develops technologies to restore function lost due to neurological injuries or diseases, such as neuromodulation systems for stroke rehabilitation. This chart, which displays the average valuation, shows that investors value the company based on the future potential of its breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cortigent Inc.
Cortigent develops neurotechnologies to restore function in patients with neurological disorders. This chart shows the market's estimate of its potential future revenue from medical device sales. It reflects investors' belief in the breakthrough nature of its technologies and their commercial potential if successfully tested and approved.
%20P%2FS%20Cortigent%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cortigent-Inc.&v=1772657813355 "The graph of the company's future (projected) P/S Cortigent Inc.")
Future (projected) P/S of the market segment - Neuro
Cortigent develops neuromodulation technologies to restore function in patients with neurological disorders, such as spinal cord injuries. The chart shows the average future sales estimate in the neuroscience sector. It helps understand how investors assess the revolutionary potential and clinical risks of Cortigent's technology in this complex area of medicine.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772657813564 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Cortigent (CRGT) develops neuromodulation technologies to restore function in patients after stroke and other neurological disorders. Their potential depends on the success of clinical trials and the implementation of their technology in medicine. This timeline does not reflect their unique potential, which lies at the intersection of medicine and technology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772657813630 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cortigent Inc.
Cortigent is at the forefront of neurotechnology development. Currently in clinical trials, the company has no stable sales revenue. It is developing devices to restore function after injury. The graph below will reflect future revenue from the commercialization of its breakthrough medical technologies after approval.
Sales of companies in the market segment - Neuro
Cortigent (formerly Chanticleer Holdings) has shifted its focus to developing neurotechnology. Its future revenue will depend on the success of its devices aimed at restoring function after injury, which is typical for a biotech company whose value is based on scientific and clinical potential.
Overall market sales
Cortigent, Inc. develops neurotechnologies aimed at restoring function after injury. As a research-stage company, its value is determined by its scientific potential. The overall economic situation, shown in this chart, influences the availability of venture capital and grant funding, which are necessary for conducting complex and lengthy clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cortigent Inc.
Cortigent develops neurotechnologies to restore function in patients with nervous system injuries, such as stroke and spinal cord injury. Future revenue depends on the success of its clinical programs. This graph represents a long-term forecast of the potential of its breakthrough therapeutic devices.
%20sales%20of%20the%20company%20Cortigent%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cortigent-Inc.&v=1772657814053 "Schedule of future (projected) sales of the company Cortigent Inc.")
Future (projected) sales of companies in the market segment - Neuro
Cortigent, Inc. develops neurostimulation technologies to restore function in patients who have suffered strokes and other neurological injuries. This chart shows the forecast for the neurological sector. It reflects the need for innovative rehabilitation methods, creating significant market potential for Cortigent's breakthrough technologies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772657814181 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Healthcare cost forecasts and investments in medical technologies are important to Cortigent. The company develops neuromodulation devices for rehabilitation. The implementation of such innovative technologies depends on research funding and the healthcare system's willingness to pay for new treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772657814247 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cortigent Inc.
Cortigent develops neurotechnologies aimed at restoring function lost due to injury or neurological disease. This chart reflects financial performance during the research and development phase. Future profitability is entirely dependent on the success of clinical trials and the commercialization of its innovative therapeutic devices.
Market segment marginality - Neuro
Cortigent develops neuromodulation technologies to help patients with neurological disorders, such as those resulting from stroke. The company's profitability will depend on the success of its clinical trials and the commercialization of this cutting-edge technology. This chart shows the average profitability in the sector, providing context for assessing the potential of Cortigent's developments.
Market marginality as a whole
Cortigent develops technologies to restore function lost due to neurological diseases. As a research-stage company, it relies on funding and successful clinical data. This chart reflects the overall investment climate and risk appetite, which determine the ease of raising capital for the development of breakthrough medical devices.
Employees in the company, segment and market as a whole
Number of employees in the company Cortigent Inc.
Cortigent, Inc. develops neuromodulation technologies to restore function after nervous system injury. This graph represents the team of scientists and engineers working on this cutting-edge technology. An upward trend on the graph indicates progress in clinical trials and progress toward commercialization of life-changing devices.
Share of the company's employees Cortigent Inc. within the market segment - Neuro
Cortigent (formerly Intelligent Implants) develops neurotechnologies to restore function lost due to injury or disease. This chart shows the percentage of all scientists and engineers in the cutting-edge field of neurostimulation that the company employs. This indicates its innovative potential and the complexity of the medical problems it solves.
Number of employees in the market segment - Neuro
Cortigent, Inc. (formerly Pioneers in Brain-Computer Interfaces) develops neurotechnologies to restore function in patients with neurological disorders. This chart showing employment in the neurotech sector is important. The growing number of neuroscientists and engineers in this cutting-edge field reflects the race to create breakthrough treatments for paralysis and blindness.
Number of employees in the market as a whole
Cortigent develops technologies to restore nervous system function. This is a cutting-edge field of medicine that requires significant investment. This overall employment chart reflects the economic stability necessary to fund such long-term R&D projects. A healthy economy ensures the influx of capital that enables scientific breakthroughs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cortigent Inc. (CRGT)
Cortigent, Inc. (formerly part of Second Sight) develops neurotechnologies, including a "bionic eye" and brain stimulators. This is the quintessence of "intellectual capital." The company's value comes from its breakthrough R&D and patents in neuromodulation. A small team of engineers and scientists is working on technologies with enormous potential market value.
%20of%20the%20company%20Cortigent%20Inc.%20(CRGT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cortigent-Inc.-CRGT&v=1772657814950 "Chart of market capitalization per employee (in thousands of dollars) of the company Cortigent Inc. (CRGT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Cortigent develops neurotechnologies to restore functions lost due to injury or disease. It's a highly research-intensive business, where all value is captured in patents and research results. This chart illustrates the enormous potential market value inherent in the work of a small team of scientists and engineers working at the cutting edge of science.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772657815044 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Cortigent develops technologies to restore nervous system function. It is a cutting-edge biomedical company. The high employee rating, shown in this graph, reflects the enormous potential of its developments to change the lives of patients, where a small team of scientists and engineers is creating revolutionary technology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772657815134 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cortigent Inc. (CRGT)
Cortigent (formerly Intelligent Bio) is a company developing medical technologies to restore function lost due to nerve damage (e.g., neurostimulators). It has deep R&D. This chart shows the company's "burn rate": how much the company spends (negative profit) on each scientist and engineer trying to commercialize this complex technology.
%20Chart%20Cortigent%20Inc.%20(CRGT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cortigent-Inc.-CRGT&v=1772657815159 "Company Profit Per Employee (in thousands of dollars) Chart Cortigent Inc. (CRGT)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Cortigent, Inc. develops neurostimulation technologies to restore function lost due to injury or disease. For a company at the forefront of medical technology, this graph reflects the efficiency of managing expensive research. Positive growth in this indicator will be directly linked to successful clinical trials and commercialization of their developments.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772657815237 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Cortigent (CRGT) is a bioelectronics company (formerly part of Second Sight) developing neurostimulators for vision restoration and other functions. It is an R&D company at the intersection of medicine and engineering. It is profit-neutral. This negative metric reflects the high cost of a single scientist/engineer working on these futuristic implants.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772657815379 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cortigent Inc. (CRGT)
Cortigent develops neurotechnologies to restore functions lost due to injury or disease. Revenue may be minimal during the research and development phase. This graph is important as an indicator of future potential: a successful technology could change lives and generate enormous revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cortigent-Inc.-CRGT&v=1772657815421 "Sales chart per company employee Cortigent Inc. (CRGT)")
Sales per employee in the market segment - Neuro
Cortigent (formerly part of Second Sight) is a biotech R&D company developing neurostimulators to restore vision and other functions. This is cutting-edge science. This chart reflects their R&D status. The productivity of their team of engineers and scientists is measured not by current sales, but by progress in creating a "bionic eye."
Sales per employee for the market as a whole
Byline Bancorp (BY) is a Chicago-based bank specializing in small and medium-sized businesses. Like most banks, its primary revenue comes from interest margins on loans and deposits. This chart illustrates operational efficiency in the banking sector, showing how much revenue each employee generates. Banks strive to increase this metric through digitalization and offering more sophisticated (and profitable) services to businesses.
Short shares by company, segment and market as a whole
Shares shorted by company Cortigent Inc. (CRGT)
Cortigent (CRGT) is developing neurotechnology in an attempt to restore function in paralyzed patients. This is cutting-edge science, but highly speculative. This chart shows the number of short positions. The bears are betting that the company's technology is too far from commercialization.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cortigent-Inc.-CRGT&v=1772657815486 "Short Shares Chart for the Company Cortigent Inc. (CRGT)")
Shares shorted by market segment - Neuro
Cortigent (CRGT) (formerly WiSA) develops neurostimulation technologies to restore function in patients with CNS damage. The chart below shows the overall short position in the biotech sector. It illustrates how skeptical investors are about the commercialization of complex neurotechnologies.
Shares shorted by the overall market
Cortigent (formerly BrainGate) develops neurotechnology, including brain-computer interfaces for paraplegic patients. It's a futuristic but highly speculative sector. This chart reflects the general fear. When investors are afraid, they don't want to fund "science fiction." They're selling off CRGT shares, fearing the technology won't be commercialized in the coming decades.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cortigent Inc. (CRGT)
This oscillator for Cortigent (formerly Second Sight) is a story of "second chances" in neurotech. The company, which went bankrupt with its "bionic eye," is now trying to use its technology for brain stimulation (stroke treatment). "Overheating" (above 70) occurs with any positive data. A history of failures and market skepticism keep the stock "oversold."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cortigent-Inc.-CRGT&v=1772657815663 "RSI 14 indicator chart for the company's stock Cortigent Inc. (CRGT)")
RSI 14 Market Segment - Neuro
Cortigent (formerly part of Pixium Vision) is a bioelectronics company. They develop "bionic" systems (implants) designed to restore vision to blind people. This is cutting-edge R&D. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry.
RSI 14 for the overall market
Cortigent (CRGT) is developing neurotechnologies aimed at restoring lost functions. This is an area of breakthrough but highly risky research. This market "temperature" chart shows when investors are willing to fund these "moonshots." During moments of euphoria (overbought), capital for R&D is available. During times of panic (oversold), investors flee stocks like CRGT.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRGT (Cortigent Inc.)
Cortigent (CRGT) is a biotech company developing neurostimulation technologies for stroke and trauma rehabilitation. This chart shows the average price target. It reflects analysts' faith in this cutting-edge technology and its potential to gain regulatory approval and medical acceptance.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRGT-Cortigent-Inc.&v=1772657815801 "A chart showing analyst consensus forecasts for the expected stock price. CRGT (Cortigent Inc.)")
The difference between the consensus estimate and the actual stock price CRGT (Cortigent Inc.)
Cortigent (CRGT) is a biotech company developing neurostimulators to restore function (speech, movement) in patients after stroke and other injuries. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this "neuroplastic" technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRGT-Cortigent-Inc.&v=1772657815856 "A chart showing the difference between the consensus forecast and the actual stock price. CRGT (Cortigent Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Cortigent is a biotech company developing "neuromodulation"—a brain stimulation technology for rehabilitation after stroke and other injuries. This chart shows the general expectations of analysts across the neuroscience sector. It reflects whether experts believe in the breakthrough of "brain-computer interfaces" in medicine.
Analysts' consensus forecast for the overall market share price
Cortigent (CRGT) is a neurotech company. They are developing a technology (VNS) that "retrains" the brain to restore function after stroke or spinal cord injury. This is breakthrough, but speculative, R&D. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough, but extremely risky, R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cortigent Inc.
Cortigent (formerly Vivani/Second Sight) is a vision battleground. It's an R&D company that has revived the technology of the bionic eye (Argus)—an implant that promises to restore sight to the blind. It's a moonshot bet on a miracle. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but a speculative estimate of their (incredibly difficult) path to FDA approval.
AKIMA Market Segment Index - Neuro
Cortigent is a neuroscience company that restores function. They develop devices that stimulate the brain or nerves to help patients recover movement after stroke or other injuries. This chart compares their composite index to the sector, showing how their advanced neuroscience technologies compare to others.
The AKIM Index for the overall market
Cortigent is a company developing neuromodulation devices for post-stroke and post-traumatic functional recovery. This chart, which reflects the market average, provides context. It helps assess how this early-stage MedTech story compares to overall macroeconomic trends.
